Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2020 | EHA and ASCO 2020 – what data will impact clinical practice?

Joshua Richter • 7 Jul 2020
ASCO 2020 EHA 2020
Multiple Myeloma Antibodies Belantamab mafodotin BiTEs Teclistamab
CARTITUDE-1 DREAMM-9

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, highlights the presentations from EHA and ASCO 2020 that will potentially have the greatest impact on clinical practice. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joshua Richter

The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
1:43
The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
Joshua Richter • 19 Sep 2025
How does linvoseltamab compare with other bispecific antibodies in multiple myeloma?
1:34
How does linvoseltamab compare with other bispecific antibodies in multiple myeloma?
Joshua Richter • 19 Sep 2025
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma
3:04
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma
Joshua Richter • 4 Mar 2025
What lies ahead for bispecifics in multiple myeloma?
2:02
What lies ahead for bispecifics in multiple myeloma?
Joshua Richter • 4 Mar 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Joshua Richter • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Joshua Richter • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Joshua Richter • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Joshua Richter • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals